JAK1 and Aicardi-Goutieres syndrome: More recently, the description of a promising effect of JAK1/2 inhibitors in AGS, used with the aim of blocking JAK1 at the type I interferon receptor, suggests that this class of drug represents an important approach to the treatment of this devastating disease [7, 8].